HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $45 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on TG Therapeutics (NASDAQ:TGTX) and maintained a $45 price target.
March 01, 2024 | 7:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White reiterates a Buy rating on TG Therapeutics with a maintained price target of $45.
The reiteration of a Buy rating and the maintenance of a $45 price target by a reputable analyst could positively influence investor sentiment towards TG Therapeutics, potentially driving up its stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100